Established in 1994, Current Oncology is a peer-reviewed, Canadian based and Internationally distributed journal. Published bi-monthly plus special supplemental issues, Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy to report upon and to review progress in the management of this disease. Current Oncology is published by Multimed Inc.
Current Oncology is indexed/covered in PubMed, EMBASE (Excerpta Medica Database), Scopus, Journal Selector, CrossRef, Index Copernicus, DOAJ (Directory of Open Access Journals), Google Scholar, EMCare, EBSCOhost.com Research Databases, Science Citation Index Expanded (SciSearch), and Journal Citation Reports/Science Edition. Following publication in Current Oncology, the full text of each article is available immediately and archived in PubMed Central (PMC), the U.S. National Library of Medicine's digital archive of biomedical and life sciences journal literature. It is also available in the databases of 100 libraries worldwide, and is a participant of the HINARI program.
The information provided on the Current Oncology website is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
Journal Announcement: New Impact Factor of 1.643 for Current Oncology!
We are pleased to announce to our readers that Current Oncology’s 2013 Impact Factor has increased to 1.643! This is an increase from our 2012 stats, where we received an impact factor of 1.625.
The journal impact factor is a measure of citation frequency that reflects the average number of citations to articles published in science and social science journals. Impact factors are calculated annually for those journals that are indexed in Thomson Reuters Journal Citation Reports. The impact factor of a journal in a given year is the average number of citations a paper published in that journal received during the two previous years. The impact factor is often used to rank the relative importance and scientific caliber of a journal within its field.
Our 2013 Impact Factor is a significant achievement for the journal, and demonstrates the increased recognition of Current Oncology in the field, and the improved relevance and quality of our articles. Thank you to our team of Editors and Section Editors, Reviewers and Authors for their valuable contribution to the journal. We look forward to continued success in 2014 as the journal continues to strengthen and grow!
GIOTRIF® (afatinib) approved by Health Canada for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation
On November 6, 2013, Health Canada approved GIOTRIF® (afatinib) a targeted, oral once-daily tyrosine kinase inhibitor and the first irreversible ErbB Family Blocker approved for the treatment of EGFR mutation positive tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) tablets.
In clinical trials, GIOTRIF® has been shown to offer patients with EGFR mutation positive NSCLC a significant delay in tumour progression,[i] coupled with improvements in their lung cancer related symptoms versus standard chemotherapy.[i]
Dr. Vera Hirsh, GIOTRIF® clinical trial investigator and medical oncologist at Royal Victoria Hospital in Montreal says, “The approval of GIOTRIF® is an exciting advancement because it works differently than other drugs in its class, by irreversibly blocking multiple EGFR pathways involved in tumour growth.”
GIOTRIF®’s unique mode of action enables it to block EGFR (ErbB1) as well as the other relevant members of the ErbB Family. The covalent and, therefore, irreversible binding of GIOTRIF® is unlike other compounds currently on the market which are reversible in that it provides a sustained, selective, and complete ErbB Family Blockade.[i],[ii]
Discovered and developed by Boehringer Ingelheim, GIOTRIF® is the first Health Canada-approved oncology product from the company.
[i] Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50.
[ii] Reid A, Vidal L, Shaw H, do Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007;43:481-9.
Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award!
Congratulations to our Deputy Editor – Dr. Phil Gold for winning the 2013 Prix du Québec award! Dr. Gold will be awarded the Wilder-Penfield Prize for his work in the ground-breaking discovery of the carcinoembryonic antigen (CEA).
The CEA was discovered in 1965 by Dr. Gold and his colleague, Samuel Freedman. This discovery revolutionized cancer research and is now the most frequently used blood test in modern oncology. The discovery of the CEA also launched the field of oncodevelopmental biology.
Thank you for your important contribution to oncology, Dr. Gold!
Vol 21, No 5 (2014)
The oil painting on the cover of this issue is entitled “Awakening.” It won Best Oil by a Person Diagnosed with Cancer in the 2010 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.
Oncology On CanvasSM is an art competition and exhibition that honours the journeys people face when confronted with a cancer diagnosis. This biennial competition invites individuals diagnosed with any type of cancer—as well as their families, friends, caregivers and healthcare providers—to express, through art and narrative, the life-affirming changes that give their cancer journeys meaning.
Oncology On Canvas was started in 2004 by Lilly Oncology to help address a great, unmet need in cancer care—a need that goes beyond medicine—to help those affected by cancer cope with the emotional toll of the disease. Since 2004, the National Coalition for Cancer Survivorship (NCCS) has been the co-presenter of the Lilly Oncology On Canvas Art Competition and Exhibition for US and Puerto Rico residents.
Lilly Oncology on Canvas Canada launched in 2014. Visit www.lillyocc.com to learn more about the competition. Lilly Oncology on Canvas Canada is presented in partnership with the Canadian Association for Psychosocial Oncology and the Canadian Cancer Survivor Network.
Current Oncology is committed to the Canadian oncology community as well as oncology communities around the world. We are pleased to help raise awareness of this great program created by Lilly. Current Oncology will be selecting new artwork for each cover from previous competitions.
Copyright © 2014 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)